Search Results
You are looking at 1 - 1 of 1 items for
- Author: A D’Antonio x
- Refine by access: All content x
Search for other papers by N Normanno in
Google Scholar
PubMed
Search for other papers by A De Luca in
Google Scholar
PubMed
Search for other papers by D Aldinucci in
Google Scholar
PubMed
Search for other papers by M R Maiello in
Google Scholar
PubMed
Search for other papers by M Mancino in
Google Scholar
PubMed
Search for other papers by A D’Antonio in
Google Scholar
PubMed
Search for other papers by R De Filippi in
Google Scholar
PubMed
Search for other papers by A Pinto in
Google Scholar
PubMed
Significant relief of bone pain in patients with bone metastases was observed in a clinical trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in breast cancer. Osteoclast activation and differentiation are regulated by bone marrow stromal cells (BMSC), a heterogeneous cell compartment that comprehends undifferentiated mesenchymal stem cells (MSC) and their specialized progeny. In this regard, we found that human primary BMSCs express immunoreactive EGFR. Expression of EGFR mRNA and protein was also demonstrated in two human, continuous MSC-like cell lines, HDS-1 and HDS-2 cells. Treatment of HDS cells with EGF produced a significant increase in the levels of activated EGFR which was not observed in the presence of gefitinib. A significant reduction in the basal levels of activation of the EGFR and of Akt was observed in HDS cells following treatment with gefitinib. Treatment of HDS cells with gefitinib produced a significant reduction in the levels of secreted macrophage colony-stimulating factor (M-CSF) and cell-associated receptor activator of NF-κB ligand (RANKL) in both cell lines, as assessed by using specific ELISA and Western blotting techniques. Finally, the ability to sustain the differentiation of pre-osteoclasts of conditioned medium from gefitinib-treated HDS cells was reduced by approximately 45% as compared with untreated HDS cells. These data have demonstrated for the first time that the EGFR regulates the ability of BMSCs to induce osteoclast differentiation and strongly support clinical trials of gefitinib in breast cancer patients with bone disease.
